SARS-CoV-2 Versus Influenza-associated Acute Respiratory Distress Syndrome Requiring Veno-venous Extracorporeal Membrane Oxygenation Supportview event
Pulsatile perfusion: What are the benefits, and do they outweigh the risks? Physiologic pulse pressure and circuit limitations will be discussed | Perfusion Educationview event
Dr. David Platt has a PhD in carbohydrate chemistry from the Weizmann Institute of Science in Israel and completed his post-doctoral work at Wayne State University in Michigan. He is a pioneer in designing drugs derived from co-polymers. He has over 30 years of experience in drug development, with over 30 patents, authored 10 journal articles, completed 2 textbooks, CEO of 5 public companies, 3 of which were NASDAQ, and conducted over 30 clinical trials. He was the very first to combine chemotherapy with a co-polymer to target cancer which radically improved the safety profile of the treatments. He coined the name Galectin and was the first to publish in a field of research that now produces over 300 peer reviewed articles annually. His life’s work is embodied in his latest invention called BXT-25 which is an oxygen transport delivery drug that is 5000 times smaller than a red blood cell and is capable of treating stroke, ARDS, and other diseases that have an element of hypoxia within the disease.